Wang Ruoyu, Zhang Zhaofeng, Aihemaitijiang Sumiya, Ye Chen, Halimulati Mairepaiti, Huang Xiaojie, Qin Haoyuan
Department of Nutrition and Food Hygiene, School of Public Health, Peking University, Beijing, China.
Beijing's Key Laboratory of Food Safety Toxicology Research and Evaluation, Beijing, China.
Front Nutr. 2022 May 9;9:875060. doi: 10.3389/fnut.2022.875060. eCollection 2022.
Diabetic nephropathy is a severe complication of diabetes and the leading cause of end-stage renal disease and death. Therefore, we must find effective prevention and treatment approaches to the problem. Oat has a long history of use for its nutritional and medicinal properties, such as maintaining physiological blood glucose levels. Oat β glucan is one of the major bioactive substances produced by oat. However, the protective effects of oat β glucan on diabetic nephropathy are still unclear. This study generated a rat model of diabetic nephropathy to explore the potent therapeutic ability and mechanism of oat β glucan in renal function by 16S rRNA genes sequencing. Diabetic nephropathy model was established in forty rats by left nephrectomy and single intraperitoneal injection of streptozotocin. These rats were randomly divided into the model group and three oat β glucan intervention groups. Twenty rats underwent sham operation and were randomly divided into normal control group and oat β glucan control group. Animals were treated by oral gavage for 8 consecutive weeks. The results showed that oat β glucan reduced blood glucose level and improved renal function ( < 0.05). Oat β glucan significantly improved serum inflammatory levels ( < 0.05). The diversity of intestinal microflora in diabetic nephropathy rats decreased with time prolongation, while oat β-glucan reversed the result. Compared with the model group at week 8, the abundances of , and were elevated significantly after oat β glucan intervention ( < 0.05). Correlation analysis indicated that abundances of , and were significantly negatively correlated with the levels of renal impairment markers. In summary, the findings of this study showed that oat β glucan can increase the diversity of intestinal flora, regulate the composition of intestinal flora, modulate intestinal flora metabolism, alleviate the inflammatory response, and further delay the development of diabetic nephropathy. Therefore, oat β glucan has the potential to be developed into the novel and safe drug for diabetic nephropathy.
糖尿病肾病是糖尿病的一种严重并发症，也是终末期肾病和死亡的主要原因。因此，我们必须找到针对该问题的有效预防和治疗方法。燕麦因其营养和药用特性，如维持生理血糖水平，有着悠久的使用历史。燕麦β-葡聚糖是燕麦产生的主要生物活性物质之一。然而，燕麦β-葡聚糖对糖尿病肾病的保护作用仍不清楚。本研究通过16S rRNA基因测序建立糖尿病肾病大鼠模型，以探讨燕麦β-葡聚糖在肾功能方面的有效治疗能力和机制。通过左肾切除和单次腹腔注射链脲佐菌素在40只大鼠中建立糖尿病肾病模型。这些大鼠被随机分为模型组和三个燕麦β-葡聚糖干预组。20只大鼠接受假手术，并随机分为正常对照组和燕麦β-葡聚糖对照组。动物连续8周经口灌胃给药。结果显示，燕麦β-葡聚糖降低了血糖水平并改善了肾功能（<0.05）。燕麦β-葡聚糖显著改善了血清炎症水平（<0.05）。糖尿病肾病大鼠肠道微生物群的多样性随时间延长而降低，而燕麦β-葡聚糖逆转了这一结果。与第8周的模型组相比，燕麦β-葡聚糖干预后，、和的丰度显著升高（<0.05）。相关性分析表明，、和的丰度与肾功能损害标志物水平呈显著负相关。总之，本研究结果表明，燕麦β-葡聚糖可增加肠道菌群的多样性，调节肠道菌群组成，调节肠道菌群代谢，减轻炎症反应，并进一步延缓糖尿病肾病的发展。因此，燕麦β-葡聚糖有潜力被开发成为治疗糖尿病肾病的新型安全药物。
